Interferon-γ release assay screening in biologics: safe and reliable, but not perfect.

John Cafferkey Yorissa PadayacheeSophia KostichKartik Kumar Paul JewellMikin PatelAneeka ChavdaAlison CoxMirae ParkGeorgina RussellMeg Coleman Laura Martin Onn Min Kon

Published in: ERJ open research (2022)

Negative IGRA results confer a low risk of subsequent active TB in patients on biologics in a low TB incidence setting. However, continued awareness is needed given that a number of active TB cases will have had a prior negative result.

Keyphrases

mycobacterium tuberculosis
end stage renal disease
newly diagnosed
chronic kidney disease
risk factors
prognostic factors
peritoneal dialysis
high throughput
immune response
patient reported